Your session is about to expire
← Back to Search
Tisagenlecleucel for Follicular Lymphoma (ELARA Trial)
ELARA Trial Summary
This trial is testing a new cancer treatment for people with a certain type of lymphoma that has returned or does not respond to other treatments.
ELARA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowELARA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 69 Patients • NCT03123939ELARA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: CTL019
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many people are being given the opportunity to participate in this particular clinical trial?
"As of now, this study has stopped recruiting patients. It was originally posted on November 12th, 2018 and edited for the last time on November 2nd, 2022. There are currently 1761 studies looking for participants with lymphoma and 18 trials searching for individuals to test tisagenlecleucel."
What are the long-term risks associated with tisagenlecleucel?
"Tisagenlecleucel's safety is based on data from Phase 2 trials, which only provide evidence of its safety and not efficacy."
What are researchers aiming to accomplish with this trial?
"The primary outcome of this study, which will be monitored over the course of 2 years, is CRR as assessed by an independent review committee. Additional secondary outcomes include T1/2; a cellular kinetic parameter defined as The half-life associated with the elimination phase slope of a semi logarithmic concentration-time curve (days) in peripheral blood, humoral immunogenicity which is measured in terms of antibody titers specific to the tisagenlecleucel molecule prior to and following infusion., and summary PRO scores as captured by the EQ-5D-3L quality of life questionnaire."
Are there any ongoing or previous research projects regarding tisagenlecleucel?
"Tisagenlecleucel is being studied in 18 different ongoing clinical trials, 2 of which are Phase 3 studies. The majority of research centres for tisagenlecleucel are located in Washington D.C., but there are a total of 331 locations where tisagenlecleucel clinical trials are taking place."
Can people with the condition still enroll in this clinical study?
"This particular study is not seeking new patients at this time, as the last update was on November 2nd, 2022. However, there are 18 other trials for tisagenlecleucel actively enrolling participants and 1761 studies involving lymphoma, follicular that are currently looking for candidates."
Share this study with friends
Copy Link
Messenger